Global Next Generation Cancer Diagnostics Industry to 2025

News provided by

Aug 26, 2020, 15:15 ET

DUBLIN, Aug. 26, 2020 /PRNewswire/ -- The "Next Generation Cancer Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

The research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

The report includes:

22 data tables and 74 additional tables
An overview of the global market and technologies for next generation cancer diagnostics
Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
Details of the key initiatives and programs related to the next generation cancer diagnostics market
Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.

Key Topics Covered

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Overview

Large-Scale Initiatives and Consortia
Market Size
Liquid Biopsy as a Market Driving Force
Key Trends
Industry

Chapter 4 Technologies

Diagnostics Overview
Arrays and Microfluidics (LOAC) Technologies
DNA Microarrays
Protein Microarrays
Microfluidics
Multiplex Conventional Technologies
Next Generation Sequencing Technology
Polymerase Chain Reaction (PCR) Technology

Chapter 5 Liquid Biopsy Technologies

Liquid Biopsy Biomarkers
Cancer Genomics
Circulating Tumor Cell Technologies
CTC Workflow
Cell Isolation Technologies
CTC Sample Preparation Technologies
CTC Downstream Analysis Technologies
Comparison of Liquid Biopsy with Conventional Biopsy
Cancer Testing
Avatar-Driven Diagnostic Approaches

Chapter 6 Next Generation Cancer Diagnostics: Key Initiatives and Programs

Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Human Cell Atlas
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring
Liquid Biopsies and Imaging for Improved Cancer Care
Million Veteran Program
MedSeq
Next-Generation Single-Cell Analysis Program
Population Sequencing Projects
Precancer Atlas
Precision Medicine Initiative
Prompt
QuIP Project
Single-Cell Proteomics and Lipidomics Project
TopMed
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Population Sequencing Programs

Chapter 7 Next Generation Cancer Diagnostic Applications by Cancer Site

Introduction
Bladder Cancer
Brain Cancer
Breast Cancer
Breast Cancer Screening
Prognosis and Pharmacogenetics Tests
Breast Cancer MDx Platforms
Status of Next Generation Breast Cancer Tests
Breast Cancer Early Detection and Screening Tests
Breast Cancer Risk Tests
Response to Chemotherapy, Recurrence Probability and Subtyping
Gynecologic Cancers
Cervical Cancer
Ovarian Cancer
Colorectal Cancer
Conventional Colorectal Cancer Screening Tests
Next Generation Colorectal Cancer Diagnostic Tests
Cancer Unknown Primary
Gastric Cancer
Kidney Cancer
Hematologic Tests: Leukemia and Myeloma
Liver Cancer
Lung Cancer
Hematologic Tests: Lymphomas
Melanoma
Pan-Cancer
Prostate Cancer
Thyroid Cancer

Chapter 8 Cancer Diagnostics Industries

Sequencing Instruments Industry
Long Read Sequencing Industry
Sequencing Informatics Industry
PCR Industry
Droplet Digital PCR Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry

Chapter 9 Industry Acquisitions and Strategic Alliances

Acquisitions
Strategic Alliances

Chapter 10 Cancer Diagnostics Markets

Forces Driving Growth
COVID-19 Impact on Cancer Diagnostic Markets
Cancer Markets
Market for Next Generation Cancer Diagnostics by Cancer Site
Bladder Cancer
Brain Cancer
Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Cancer of Unknown Primary
Gastric Cancer
Hematologic Cancers
Kidney Cancer
Liver Cancer
Lung Cancer
Melanoma
Pan-Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Market for Next Generation Cancer Diagnostics by Purpose of Analysis
Screening/Early Detection Market
Diagnosis Market
Therapy Guidance Market
Monitoring Market
Market for Next Generation Cancer Diagnostics by Test Platform
PCR Test Platform
NGS Test Platform
Array/Microfluidics Test Platform
Cells and/or EV Capture Test Platform
Multiplex Conventional Test Platform
Market for Test Platforms by Cancer Site
PCR Test Platform
NGS Test Platform
Market by Diagnostic Segment
Screening/Early Detection Market
Diagnostics Market
Monitoring Market
Therapy Guidance Market
Breast Cancer Diagnostics
Colorectal Cancer Diagnostics
Lung Cancer Diagnostics
Pan-Cancer Diagnostics
Prostate Cancer Diagnostics
Regional Market Analysis

Chapter 11 Patents

Circulating Tumor Cell Patents
Exosome Patents
Cell-free DNA (cfDNA) Patents
Biomarker-Related Patents
Patent Considerations: AI in Cancer Diagnostics

Chapter 12 Company Profiles

20/20 Gene Systems
Abbott Laboratories
Adaptive Biotechnologies Inc.
Agendia Nv
Agilent Technologies Inc.
Akadeum Life Sciences
Ambry Genetics
Amoy Diagnostics Co. Ltd.
Angle Plc
Apocell Inc.
Apostle Inc.
Arbor Vita Corp.
Archer Dx
Arocell Ab
Arup Laboratories
Aspira Labs
Asuragen, Inc.
Atila Biosystems
Aviva Biosciences
Becton, Dickinson And Co.
BGI Shenzhen
Bio-Techne Corp.
Biocartis Nv
Biocept Inc.
Biodesix Inc.
Biofidelity Ltd.
Biofluidica Inc.
Biolidics Ltd.
Biological Dynamics Inc.
Bioprognos Sl
Biotheranostics Inc.
Bluestar Genomics Inc.
Cancer Genetics Inc.
Caris Life Sciences
Castle Biosciences Inc.
CC Diagnostics Bv
Celcuity Inc.
Cell Microsystems Inc.
Cellmax Life
Cellular Analytics
Celsee Diagnostics
Chip Diagnostics
Chronix Biomedical
Circulogene Theranostics
Clinical Genomics Technologies
Codiak Biosciences
Danaher Corp.
Decipher Biosciences
Dermtech
Diacarta Inc.
Dnalytics
Epic Sciences Inc.
Epigenomics Ag
Exact Sciences Corp.
Fluxion Biosciences Inc.
Freenome Inc.
Fulgent Genetics Inc.
Genecentric Therapeutics
Genedx Inc.
Geneoscopy Llc
Genera Biosystems
Geneseq Biosciences Pty Ltd.
Genetron Health Technologies Inc.
Genexosome Technologies Inc.
Grail Inc.
Guardant Health Inc.
Hologic Inc.
HTG Molecular Diagnostics Inc.
IDL Biotech
Illumina Inc.
Immunis Ai
Incelldx Inc.
Inivata Ltd.
Interpace Biosciences Inc.
Invitae Inc.
Invivoscribe Inc.
JBS Science Inc.
Laboratory Corp. Of America Inc.
Lexent Bio Inc.
Lucence Diagnostics Pte. Ltd.
Lunglife Ai, Inc.
MDNA Life Sciences Inc.
Mdxhealth Inc.
Medgenome Inc.
Menarini Silicon Biosystems Spa
MIR Scientific
Miradx
Mutantdx
My Personal Therapeutics Ltd.
Myriad Genetics Inc.
Neo New Oncology Gmbh
Neogenomics Laboratories
Nodexus
Novigenix Sa
Nrich Dx
Nucleix
Nuprobe Inc.
Oncimmune Holdings Plc
Oncocyte Corp.
Oncodna S.A.
Opko Health
Oxford Gene Technology
Pacific Edge Ltd.
Pangaea Laboratory
Pangaea Oncology
Personal Genome Diagnostics Inc.
Polymedco, Inc.
Predicine Inc.
Provista Diagnostics Inc.
Qiagen Nv
Quantumdx
Quest Diagnostics Inc.
Rarecyte Inc.
Resolution Bioscience Inc.
Roche Holding Ag
Saga Diagnostics Ab
Sanomics Ltd.
Sienna Cancer Diagnostics Ltd.
Singlera Genomics Inc.
Sistemas Genomicos
Skylinedx Bv
Stage Zero Life Sciences
Strand Life Sciences Pvt., Ltd.
Sysmex Inostics Gmbh
Thermo Fisher Scientific Inc.
Thrive Earlier Detection Corp.
Tiziana Life Sciences Plc
Veracyte
Volitionrx
Vortex Biosciences
Xing Technologies Llc
Yikon Genomics Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/uy3sdd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets